After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
